基于真实世界数据制定循证临床方案:用[177Lu]Lu-PSMA放射性药物治疗监测转移性去势抵抗性前列腺癌疗效
本研究回顾性纳入2019年4月至2023年11月接受至少2周期[177Lu]Lu-PSMA治疗的转移性去势抵抗性前列腺癌患者,按RECIP 1.0视觉评估治疗后SPECT/CT的预后价值。SPECT进展与较短总生存相关,SPECT+PSA与PET+PSA的预后准确度无显著差异。
要点
- SPECT进展者总生存较稳定者短(HR 2.5;95%CI 1.2-5.3;P=0.015)
- SPECT进展者总生存较部分缓解者短(HR 6.5;95%CI 2.7-15.7;P<0.001)
- SPECT+PSA与PET+PSA的C指数无显著差异(0.62 vs 0.66;P=0.07)
核心结论
- 2周期治疗后按RECIP 1.0评估的LuPSMA SPECT/CT对总生存有预后价值。
- LuPSMA SPECT/CT识别出的RECIP进展患者显著更少,但SPECT+PSA对LuPSMA疗效评估的预后准确度与PET+PSA相似。
研究设计与样本
- 回顾性纳入2019年4月至2023年11月接受至少2周期LuPSMA治疗的转移性去势抵抗性前列腺癌患者。
- 分析基线与2周期治疗后LuPSMA SPECT/CT及PSMA PET/CT图像,按RECIP 1.0视觉评估。
- 将12周时PSA变化按PCWG3指南分类,与RECIP 1.0判读结合为复合分类方法(PSA+RECIP)判定疾病进展。
- 主要结局为治疗后SPECT按RECIP 1.0评估对总生存的预后价值。
- 基于SPECT与PET、SPECT+PSA与PET+PSA的预后准确度(Harrell C指数)制定临床方案。
主要发现
- 共评估105例患者数据。
- SPECT判定进展者总生存较稳定者短(HR 2.5;95%CI 1.2-5.3;P=0.015)。
- SPECT判定进展者总生存较部分缓解者短(HR 6.5;95%CI 2.7-15.7;P<0.001)。
- 73例2周期后行PET检查的患者中,SPECT、PET、SPECT+PSA、PET+PSA显示肿瘤进展者分别为7例(10%)、30例(41%)、22例(30%)、30例(41%)。
- SPECT的C指数低于PET(0.54 vs 0.66;P<0.001),SPECT+PSA与PET+PSA的C指数无显著差异(0.62 vs 0.66;P=0.07)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objectives were to assess the prognostic value of posttherapy [177Lu]Lu-PSMA (LuPSMA) SPECT/CT by visual evaluation using RECIP 1.0 during LuPSMA therapy and develop an evidence-based clinical protocol to monitor the efficacy of LuPSMA. Methods: Patients with metastatic castration-resistant prostate cancer who received at least 2 LuPSMA cycles between April 2019 and November 2023 were retrospectively included in this study. Pairs of baseline and interim LuPSMA SPECT/CT (SPECT) and PSMA PET/CT (PET) images after 2 therapy cycles were analyzed per visual RECIP 1.0. Changes in prostate-specific antigen (PSA) levels at 12 wk were categorized by Prostate Cancer Working Group Criteria 3 guidelines and combined with RECIP 1.0 reads to determine disease progression using a composite classification method (PSA + RECIP). The primary outcome was the prognostic value of posttherapeutic SPECT by RECIP 1.0 for overall survival (OS). The clinical protocol was developed on the basis of the prognostic accuracy (Harrell concordance index, or C-index) of SPECT versus PET and the combination of SPECT plus PSA (SPECT + PSA) versus the combination of PET plus PSA (PET + PSA). Results: Data from 105 patients were evaluated. Progressive disease determined by SPECT was associated with shorter OS compared with stable disease (hazard ratio, 2.5; 95% CI, 1.2-5.3; P = 0.015) and with partial response (hazard ratio, 6.5; 95% CI, 2.7-15.7; P < 0.001). Of the 73 patients who underwent PET after 2 cycles, 7 (10%), 30 (41%), 22 (30%), and 30 (41%) had tumor progression shown by SPECT, PET, SPECT + PSA, and PET + PSA, respectively. The C-index for SPECT was inferior compared with that for PET (0.54 vs. 0.66; P < 0.001), whereas the C-indices for SPECT + PSA and PET + PSA did not differ significantly (0.62 vs. 0.66, respectively; P = 0.07). Conclusion: Posttherapeutic LuPSMA SPECT/CT per RECIP 1.0 after 2 therapy cycles was prognostic for OS. LuPSMA SPECT/CT identified significantly fewer patients with RECIP-classified progressive disease; however, SPECT + PSA achieved similar prognostic accuracy to PET + PSA for LuPSMA response evaluation.
引用
- Unterrainer LM, De Leiris N, Unterrainer M, et al. Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. J Nucl Med. 2025. PMID: 40274370. doi:10.2967/jnumed.124.269431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。